TG Therapeutics, Inc. (TGTX)
NASDAQ: TGTX · Real-Time Price · USD
34.99
+1.35 (4.01%)
At close: May 12, 2025, 4:00 PM
34.72
-0.27 (-0.77%)
After-hours: May 12, 2025, 7:56 PM EDT
TG Therapeutics Revenue
TG Therapeutics had revenue of $120.86M in the quarter ending March 31, 2025, with 90.40% growth. This brings the company's revenue in the last twelve months to $386.39M, up 33.54% year-over-year. In the year 2024, TG Therapeutics had annual revenue of $329.00M with 40.80% growth.
Revenue (ttm)
$386.39M
Revenue Growth
+33.54%
P/S Ratio
13.17
Revenue / Employee
$1,143,154
Employees
338
Market Cap
5.10B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 329.00M | 95.34M | 40.80% |
Dec 31, 2023 | 233.66M | 230.88M | 8,290.02% |
Dec 31, 2022 | 2.79M | -3.90M | -58.36% |
Dec 31, 2021 | 6.69M | 6.54M | 4,300.66% |
Dec 31, 2020 | 152.00K | - | - |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
TGTX News
- 7 days ago - TG Therapeutics Falls Short On Earnings, But Briumvi Sales Steal the Show - Benzinga
- 7 days ago - TG Therapeutics: Share Price Slip On Q1 Earnings Unsurprising Given Challenges - Seeking Alpha
- 7 days ago - TG Therapeutics, Inc. (TGTX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance - GlobeNewsWire
- 12 days ago - TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update - GlobeNewsWire
- 4 weeks ago - TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting - GlobeNewsWire
- 5 weeks ago - TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals - GlobeNewsWire
- 7 weeks ago - Stock Of The Day: TG Therapeutics Breaks Out, May Head Higher - Benzinga